Lupin Share Price

Dr Desh Bandhu Gupta founded in 1968 in Mumbai, Lupin is one of the top pharmaceutical manufacturers. It has 15 manufacturing facilities, 6 API facilities, 7 research facilities and more than 23 global offices. 

Lupin ranks 6th by sales in India. It ranks #2 in respiratory and #3 in cardiac and anti-diabetes segments. While the market growth in the chronic disease portfolio has been 11% in the last five years, Lupin has been growing at 14% YoY.
 
Over the last 4 years, it has invested over $1bn in R&D in areas of biosimilars, complex generics, long-acting complex injectables, inhalation and speciality portfolio. 

Business Verticals

1. Global Formulations
2. Active Pharmaceuticals Ingredients (API)
3. Biotech
4. Specialty Business
5. Over The Counter (OTC)
6. Biosimilars
7. Generic drugs

Company History

Lupin commenced operations in 1968 on Gudi Padwa as a vitamins manufacturer. It is named after the Lupin flower, which can tolerate infertile soils and poor climatic conditions. Its first major order was iron and folic acid tablets for mother and child healthcare programmes backed by the Government of India.

Today, it develops branded and generic formulations, APIs, and biotechnology products and sells across 100 markets, including the US, Japan, and Mexico. Lupin is one of the world's largest manufacturers of TB drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective, and Non-Steroidal Anti-Inflammatory Drugs. 
 

Milestones
 

1968 - Dr Desh Bandhu Gupta started Lupin.

1972 - Lupin Laboratories Pvt. Ltd. was incorporated.

1979 - They commissioned the first formulation plant and R&D Centre at Aurangabad.

1981 - They started the production of Ethambutol.

1987 - Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar went on stream.

1988 - Commenced Lupin Human Welfare and Research Foundation (LHWRF).

1989 - Started Lupin Chemicals (Thailand) Ltd. Received U.S. FDA approvals for the Ankleshwar and Mandideep plants.

1991 - Initiated the production of injectable Cephalosporin at Mandideep.

1992 - Commenced a sterile fermentation plant for injectable Cephalosporins at Mandideep.

1993 - Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated their IPOs.

1997 - Three facilities received U.S. FDA approvals.

2000 - Another plant received US FDA approval.

2001 - Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd. to form Lupin Ltd. and established the Lupin Research Park in Pune. Lupin became the only Asian pharmaceutical company to receive U.S. FDA approvals for its sterile Cephalosporin facility.

2002 - ORG-Marg rated Rablet as the 2nd best launch of 2002-03; patent filings exceed 100.

2003 - Received WHO approval for the formulation plant at Aurangabad. Lupin Pharmaceuticals Inc. USA is formed.

2004 - Started U.S. brands’ business with the launch of Suprax.

2005 - Commenced its generics business in the U.S. Implemented ESOP.

2006 - Announced the issue of FCCBs, with a listing on the Singapore Stock Exchange.

2007 - Acquired Kyowa Pharmaceuticals of Japan; and Rubamin Laboratories of India.

2008 - Acquired Hormosan Pharma GmbH, Germany. Also acquired stakes in Generic. Health Pty Ltd., Australia and Pharma Dynamics, South Africa.

2009 - Acquired majority stake in Multi-Care Pharmaceuticals Inc., Philippines.

2010 - Lupin ranked the 5th largest generic player in the U.S.

2011 - Began commercial production at the new oral solid dosage facility at Pithampur; acquired I’rom Pharmaceuticals, Japan and of worldwide rights for the Goanna Brand.

2012 - Lupin enters Nifty 50.

2014 - Acquired Nanomi BV of the Netherlands and Laboratorios Grin S.A. De C.V., Mexico.

2015 - Acquired Pharma Dynamics, South Africa, Medquimica Industria, Brazil; Specialty product portfolio of Temmler Pharma GMBH & Co., Germany.

2016 - Acquired Gavis Pharma, U.S; launched a new plant at Tottori, Japan.

2017 - Launched Softovac in the OTC segment; acquired Symbiomix Therapeutics, U.S.

2019 - Divestment of Kyowa Pharmaceutical Industry Co. Ltd in Osaka.

2020 - Launched Etanercept Biosimilar in EU and gProAir, a key inhalation product.